1. Pink Sheet
  2. >>R&D

Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form

 
• By Daqing Hartwell

“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.

With the eye-catching commercial success of new treatments for wet age-related macular degeneration, venture capital investors as well as industry players are turning their attention to the non-exudative form of the disease, dry AMD.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D